Aurobindo Pharma

PRESS ROOM

Aurobindo records improved performance quarter on quarter
Successful USFDA Inspection of one more Unit
Obtains 3^rd product approval from USFDA

Aurobindo receives US FDA approval for Citalopram
A robust generic product portfolio to unveil.

Aurobindo obtains two product approvals from US FDA
Records Rs.272 crore turnover in Q2

First product approval from US FDA received Foray into Regulated Market crosses first major milestone

Company scientists conferred awards

Speech by the Chairman, Mr. P. V. Ramaprasad Reddy at the Annual General Meeting on 31^st July 2004

Aurobindo posts Rs.2873 Millions sales and Rs.180 Million profit

Aurobindo net profit at Rs. 127 crs surges by 23%

UK MHRA (UK MCA) approval received for Unit 3

Subscription to preferential issue of equity shares

Aurobindo Q3 PAT grows by 68% Exports soar to 51% of sales

Aurobindo gets its first CoS approval from EDQM & files DMF for Citalopram

Aurobindo's Q2 Net Profit jumps to Rs.321.5 million, spurt by 57%

Preferential Issue of Equity Shares

Aurobindo net profit spurts by 52.75% in Q1

Aurobindo crosses the landmark Net Profit of Rs.100 crores

Aurobindo's demonstration of R&D leadership in cephalosporins

Aurobindo Pharma launches cefepime

Second quarter profit jumps 41.13%

Aurobindo implementing ERP package

First quarter profit jumps 34%

Aurobindo posts Net Profit of Rs. 68.51 crores

Noted Cardiologist Dr. I. Satyamurthy joins Aurobindo Board

Aurobindo Pharma wins award for the best bulk drug company

Shares allotted to Templeton

Brazilian GMP certification received for the speciality generic formulations unit

Aurobindo Pharma acquires equity in Ranit Pharma

Mr. Lanka Srinivas inducted as Additional Director on Board of Aurobindo Pharma

Aurobindo Pharma launches Aztreonam for the first time in India

Aurobindo Pharma & Citadel promote a joint venture

Aurobindo Pharma welcomes excise duty exemption on anti-HIV drugs in budget

Aurobindo launches Cefactam (Cefoperazone plus Salbactam)

4^th generation Cephalosporin – Cefpirome launched

Impressive Q3 performance

Aurobindo shareholders approve Rs.125 crore Private Placement

Templeton to pick up equity

Aurobindo Pharma Board approves Rs. 125 crore private placement

Restructuring on track

Aurobindo introduces two more drugs for treatment of Aids

Imunus Aurobindo launches two new anti-aids drugs

Aurobindo Pharma slashes prices of anti-aids drugs

Restructuring of Facilities

Income crosses Rs. 1000 crore land mark

www.aurobindo.com

Hyderabad, 06November, 2001

AUROBINDO PHARMA LAUNCHES TWO MORE ANTIRETROVIRAL PRODUCTS FOR HIV TREATMENT

Imunus Aurobindo, a division of Aurobindo Pharma, continues its pioneering role with new formulations for the treatment of AIDS.

Imunus Aurobindo has now launched two-fixed dose combinations, STAVEX-LN and STAVEX-L. STAVEX-LN is a combination of Stavudine 30mg, Lamivudine 150mg and Nevirapine 200mg. STAVEX-L is a combination of Stavudine 30mg and Lamivudine 150mg.

Both these combinations are very widely used in HIV treatment. These combinations reduce the number of pill consumption by patients and improve easier adherence to treatment.

According to Mr. Hariharan, Vice-President, Imunus Aurobindo "Strict adherence is an important factor in the treatment of AIDS. Patients usually forget to consume pills due to complex dosing of antiretrovirals. This introduction of fixed dose combinations will definitely simplify the pill burden for AIDS patients".

The fixed dose combinations bring down the monthly cost of treatment significantly by around 20%, making the treatment affordable to many more patients.

Backed by the Rs.75 crore R&D investment of Aurobindo Pharma Limited, Imunus is planning to launch several more fixed dose combinations in future.

Top

________________________________________________________________